Skip to main content

Table 1 pSLE patients, JIA patients, and healthy controls

From: IgG and IgA autoantibodies against L1 ORF1p expressed in granulocytes correlate with granulocyte consumption and disease activity in pediatric systemic lupus erythematosus

Characteristic

Active pSLE (n = 30) ± SD

Inactive pSLE (n = 30) ± SD

Age

14.7 ± 2.9

14.9 ± 2.6

Laboratory measures:

 C3

77.3 ± 34.1

99.9 ± 20.0

 C4

9.1 ± 7.8

16.2 ± 8.1

 ESR

39.1 ± 33.6

16.1 ± 14.2

 ANA

29

29

 Anti-dsDNA pos.

20

15

Disease activity and ACR criteria:

 SLEDAI

10.6 ± 4.8

2.4 ± 1.8

 SLEDAI = 0

1

9

 Arthritis

23

 

 Oral ulcers

13

 

 Rash

  

 Nephritis

12

 

 Pleuritis/pericarditis

9

 

 CNS symptoms

1

 

 Photosensitivity

7

 

Current treatment:

 None

10

3

 Hydroxychloroquine

16

24

 Steroid

16

22

 Other DMARD

13

19

 Biologic only

1

1

Characteristic

JIA (n = 32) ± SD

Healthy children (n = 37) ± SD

Age

13.9 ± 2.2

12.3 ± 4.4

JIA subtype:

 Persistent oligoarticular

7

 

 Extended oligoarticular

6

 

 Polyarticular RF−

17

 

 Polyarticular RF+

2

 

Active disease

24

na

Active joints

3.3 ± 3.6

na

Laboratory measures:

 RF positive

2

nd

 ACPA positive

2

nd

 ESR

11.2 ± 9.5

nd

 CRP

0.9 ± 0.9

nd

Current treatment:

 None or NSAID only

7

na

 Methotrexate only

8

na

 Other DMARD only

3

na

 Biologic only

6

na

 DMARD + biologic

8

na